SCHEMBL15041407

SCHEMBL15041407

Cc1nccn1S(C)(=O)=O

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
RECQL P46063 1/20 0.45
SMN1; SMN2 Q16637 3/20 0.44
POLB P06746 2/20 0.43
HTT P42858 1/20 0.43
KMT2A Q03164 3/20 0.42
KDM4E B2RXH2 1/20 0.42
TSHR P16473 1/20 0.42
HSD17B10 Q99714 1/20 0.42
ALDH1A1 P00352 3/20 0.41
RAB9A P51151 1/20 0.41
CA12 O43570 1/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
CA9 Q16790 1/20 0.38
HTR6 P50406 1/20 0.34
LMNA P02545 1/20 0.33
FDPS P14324 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8148844 0.84 RECQL (0.46) RECQLSMN1; SMN2POLBHTTKMT2A
SCHEMBL28827551 0.80 RECQL (0.44) RECQLSMN1; SMN2POLBHTTKMT2A
SCHEMBL27203361 0.80 RECQL (0.44) RECQLSMN1; SMN2POLBHTTKMT2A
SCHEMBL21034083 0.80 RECQL (0.44) RECQLSMN1; SMN2POLBHTTKMT2A
SCHEMBL28175124 0.80 POLB (0.45) RECQLSMN1; SMN2POLBHTTKMT2A
SCHEMBL2053373 0.77 KDM4E (0.45) RECQLSMN1; SMN2POLBHTTKMT2A
SCHEMBL5805673 0.76 SMN1; SMN2 (0.36) RECQLSMN1; SMN2HTTTSHRHTR6
SCHEMBL23701634 0.75 KMT2A (0.41) RECQLSMN1; SMN2POLBHTTKMT2A
Sulfuric Acid SCHEMBL22462539 0.75 RECQL (0.41) RECQLSMN1; SMN2POLBHTTKMT2A
SCHEMBL8636455 0.74 ESR1 (0.45) KDM4ETSHRALDH1A1RAB9ACA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8912203-B2 6-(sulfonylaryl)pyrido[2,3-D]pyrimidin-7(8H)-ones for the treatment of CNS disorders AFRAXIS HOLDINGS, INC. (US) 2014-12-16 US disclosed
US-20130252966-A1 6-(SULFONYLARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS AFRAXIS, INC. (US) 2013-09-26 US disclosed
US-20130158043-A1 PAK INHIBITORS FOR THE TREATMENT OF CANCER AFRAXIS, INC. (US) 2013-06-20 US disclosed
CN-1057091-C Novelc arbapenem derivatives MEIJI SEIKA CO (JP) 2000-10-04 CN disclosed
CN-1148390-A Novelc arbapenem derivatives MEIJI SEIKA CO (JP) 1997-04-23 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130252966-A1 6-(SULFONYLARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS PAK2, PAK6, PAK3 RECQL 2409/4885SMN1; SMN2 423/4885POLB 4522/4885
US-20130158043-A1 PAK INHIBITORS FOR THE TREATMENT OF CANCER PAK5, PAK2, PAK6 RECQL 1937/4885SMN1; SMN2 3156/4885POLB 2459/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.